Which cancer is commonly associated with the presence of the V600E mutation of the BRAF gene?

Which cancer is commonly associated with the presence of the V600E mutation of the BRAF gene?

• A. Breast cancer
• B. Colorectal cancer
• C. Malignant melanoma
• D. Lung cancer

Answer: (C)

The presence of the V600E mutation in the BRAF gene is most commonly associated with malignant melanoma. This mutation results in the production of a constitutively active BRAF protein, which plays a crucial role in the mitogen-activated protein kinase (MAPK) signaling pathway that regulates cell growth and division. In melanoma, this mutation contributes to the pathogenesis of the disease, leading to increased tumor proliferation and survival. BRAF mutations, particularly the V600E variant, are found in a significant percentage of melanoma cases, making it a key target for specific therapies. Targeted therapies, such as BRAF inhibitors, have been developed to treat melanoma patients with this mutation, showcasing the significance of genetic testing in guiding personalized treatment approaches. In contrast, while BRAF mutations can also be found in other cancers, such as colorectal cancer and lung cancer, the proportion of cases with the V600E mutation is notably lower compared to malignant melanoma. Breast cancer generally does not have a strong association with BRAF mutations in terms of the V600E variant, further highlighting the specific link between this mutation and melanoma.

The presence of the V600E mutation in the BRAF gene is most commonly associated with malignant melanoma. This mutation results in the production of a constitutively active BRAF protein, which plays a crucial role in the mitogen-activated protein kinase (MAPK) signaling pathway that regulates cell growth and division. In melanoma, this mutation contributes to the pathogenesis of the disease, leading to increased tumor proliferation and survival.

BRAF mutations, particularly the V600E variant, are found in a significant percentage of melanoma cases, making it a key target for specific therapies. Targeted therapies, such as BRAF inhibitors, have been developed to treat melanoma patients with this mutation, showcasing the significance of genetic testing in guiding personalized treatment approaches.

In contrast, while BRAF mutations can also be found in other cancers, such as colorectal cancer and lung cancer, the proportion of cases with the V600E mutation is notably lower compared to malignant melanoma. Breast cancer generally does not have a strong association with BRAF mutations in terms of the V600E variant, further highlighting the specific link between this mutation and melanoma.